Tranexamic acid reduces melasma severity by interrupting the UV-driven signalling that switches on pigment production. The pooled evidence supports oral, topical, and intradermal routes, with the largest and most consistent improvement in Melasma Area and Severity Index seen with the oral form. It is an adjunct, not a cure, and in the UK the oral route is a prescriber decision.
What tranexamic acid does in the skin
Tranexamic acid is a lysine analogue. Its original and licensed use is as an antifibrinolytic: it blocks plasminogen from converting to plasmin, which is how it controls heavy menstrual bleeding and surgical haemorrhage. The pigment effect is a second, separate mechanism that the dermatology literature has spent the last decade mapping.
Ultraviolet exposure activates plasmin in keratinocytes. That plasmin raises arachidonic acid and alpha-melanocyte-stimulating hormone, both of which drive melanocytes to produce more melanin. By dampening keratinocyte plasmin activity, tranexamic acid turns down that upstream signal. It also appears to reduce the dermal vascularity and mast-cell activity that contribute to the stubborn, relapsing nature of melasma.
This matters clinically because melasma is not a surface problem. It is a chronic, hormonally and UV-sensitive condition with a vascular component. An agent that works on the signalling layer rather than only bleaching the surface is a different category of tool from the topicals most clinics reach for first.
What the evidence actually shows
Two independent systematic reviews reach the same conclusion. The 2018 meta-analysis in BioMed Research International pooled randomised and comparative data and found tranexamic acid significantly reduced both the Melasma Area and Severity Index and the Melanin Index, with no meaningful change in the Erythema Index and only minor side effects.
The earlier Acta Dermato-Venereologica review pooled eleven studies covering 667 participants. It reported a MASI reduction of 1.60 for tranexamic acid used alone, and a further 0.94 reduction when it was added to routine treatment such as topical depigmenting agents or laser. That second figure is the practical headline: the strongest evidence is for tranexamic acid as an adjunct that lifts the ceiling on what conventional management achieves, not as a standalone replacement for it.
Across both reviews the safety signal was consistent and mild. The reported effects were gastrointestinal upset, reduced menstrual flow, occasional skin irritation, and rare urticarial reactions. No study population showed the thromboembolic events that the drug's antifibrinolytic action would raise as a theoretical concern at the low doses used for pigment.
Oral, topical, or intradermal
The route changes both the effect size and the risk profile.
- Oral. The largest MASI reductions in the pooled data come from the oral route, typically studied at low doses such as 250 mg twice daily over eight to twelve weeks. This is also the route that carries the systemic considerations below.
- Topical. Formulations in the 2 to 5 percent range show measurable benefit with negligible systemic exposure, which makes topical tranexamic acid the lower-risk entry point and the one most relevant to non-prescribing practitioners.
- Intradermal. Microinjection has evidence too, though the data set is smaller and the technique sits firmly within trained injector scope.
Relapse is the recurring theme regardless of route. Melasma returns when treatment stops and when sun exposure resumes, which is why the literature frames tranexamic acid as part of a maintenance strategy built on rigorous photoprotection rather than a fixed course with an endpoint.
The UK regulatory reality practitioners cannot skip
Oral tranexamic acid is a prescription-only medicine in the UK. It is licensed for menorrhagia and haemorrhage, not for melasma, so every oral use in pigment is off-label. That has direct consequences for who can do what.
Initiating oral tranexamic acid is a prescribing decision. It requires a prescriber working within their competence, a documented off-label rationale, informed consent that names the off-label status, and screening for thromboembolic risk: personal or family history of clot, current combined hormonal contraception, smoking, and relevant cardiovascular history all need to be weighed before a prescription is appropriate. The prescribing standards that govern this are not optional, and a non-prescriber cannot lawfully start a patient on oral tranexamic acid for pigment.
Topical tranexamic acid sits in a different place. As a cosmetic-grade active it is widely available in professional skincare ranges and does not carry the same prescribing gate. For a clinic building a pigment offering without a prescriber on the team, topical formulations combined with a structured photoprotection protocol are the defensible starting point. The JCCP scope for non-surgical procedures expects documented training behind any active you introduce, and as the licensing framework for aesthetic practice tightens, that documentation stops being good practice and becomes the baseline.
Where it fits alongside the topicals you already use
Tranexamic acid does not replace the well-evidenced pigment topicals. It complements them. Azelaic acid and niacinamide both have strong individual evidence in pigment and pair logically with tranexamic acid in a layered protocol, each working on a different point in the melanogenesis pathway.
Patient selection is where this gets clinical. Melasma and post-inflammatory hyperpigmentation are different conditions with different drivers, and knowing which one you are treating changes the plan. Tranexamic acid has its clearest evidence in true melasma, where the UV-plasmin-vascular mechanism is central. Reaching for it in every pigment presentation is how a good tool gets a reputation it does not deserve.
If you are building structured pigment management into your clinic, Hyperpigmentation Decoded covers the full clinical picture: how to read the presentation, sequence the actives, and set patient expectations for a condition that relapses. The wider course catalogue sits alongside it for practitioners formalising their clinical and regulatory footing.
FAQ
Is tranexamic acid licensed for melasma in the UK?
No. Oral tranexamic acid is licensed for menorrhagia and haemorrhage. Its use in melasma is off-label, which means a prescriber must document the rationale, gain informed consent that names the off-label status, and remain accountable for the decision. Topical tranexamic acid is available as a cosmetic active and does not carry the same prescribing requirement.
Does tranexamic acid actually work for melasma?
The pooled evidence says yes. Two independent systematic reviews found significant reductions in the Melasma Area and Severity Index, with the strongest effect when oral tranexamic acid is added to existing topical or laser treatment rather than used alone. It improves outcomes; it does not cure a chronic, relapsing condition.
Can a non-prescriber offer tranexamic acid for pigment?
A non-prescriber cannot initiate oral tranexamic acid, because it is a prescription-only medicine. Topical tranexamic acid is a different matter and can be used within a cosmetic skincare protocol, provided the practitioner holds appropriate training and documents it.
How quickly does it work?
Trials typically ran for eight to twelve weeks before measuring improvement, and benefit builds gradually over that window. Because melasma relapses when treatment stops and when sun exposure resumes, the evidence frames tranexamic acid as part of an ongoing maintenance approach anchored in photoprotection, not a fixed course with a finish line.
What are the main safety concerns?
In the pooled data the side effects were minor: gastrointestinal upset, reduced menstrual flow, and occasional skin irritation. The theoretical concern with any antifibrinolytic is clot risk, which is why screening for personal or family thromboembolic history, combined hormonal contraception, and cardiovascular risk is essential before oral use is considered.